{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Metastatic&page=2", "query": { "condition": "Melanoma Metastatic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1219, "total_pages": 122, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Metastatic&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Metastatic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T17:44:49.421Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01218867", "title": "CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Metastatic Melanoma", "Renal Cancer" ], "interventions": [ { "name": "Anti-VEGFR2 CAR CD8 plus PBL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2010-11-10", "completion_date": "2015-12-15", "has_results": true, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218867" }, { "nct_id": "NCT00072345", "title": "Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "lomustine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072345" }, { "nct_id": "NCT06101134", "title": "A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "relatlimab+nivolumab", "type": "DRUG" }, { "name": "relatlimab+nivolumab+rHuPH20", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "nivolumab+rHuPH20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-11-06", "completion_date": "2026-12-21", "has_results": true, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 9, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • San Francisco, California + 6 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Edgewood", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06101134" }, { "nct_id": "NCT05169437", "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Breast Tumor", "Colon Tumor, Malignant", "Lung Tumor", "Urologic Cancer", "Pancreatic Cancer", "Melanoma", "Metastatic Cancer", "Locally Advanced Solid Tumor", "Esophageal Cancer", "Endometrial Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-03-15", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 80, "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169437" }, { "nct_id": "NCT04387071", "title": "CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949", "type": "BIOLOGICAL" }, { "name": "VLP-encapsulated TLR9 Agonist CMP-001", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-04-29", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387071" }, { "nct_id": "NCT05578872", "title": "A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Cutaneous Melanoma", "Adult Disease", "Advanced Solid Tumor", "Metastatic Melanoma" ], "interventions": [ { "name": "ANV419", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anaveon AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2022-12-16", "completion_date": "2024-08-01", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 9, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05578872" }, { "nct_id": "NCT02273219", "title": "Trial of AEB071 in Combination With BYL719 in Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "AEB071", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2014-11-19", "completion_date": "2018-07-02", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 3, "location_summary": "Miami, Florida • New York, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273219" }, { "nct_id": "NCT01701037", "title": "Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIB Melanoma (Locally Advanced)", "Stage IIC Melanoma (Locally Advanced)", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma (Limited, Resectable)" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 13, "start_date": "2013-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-06-23", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701037" }, { "nct_id": "NCT00758797", "title": "A Novel Treatment for Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Photoimmunotherapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2008-04", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00758797" }, { "nct_id": "NCT00017355", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor Health Care System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-10-01T17:44:49.421Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017355" } ] }